*Obesity GLP-1 Wegovy and Zepbound Source: IQVIA Analysis
Through systematic analysis of clinical trials, meta-analyses, and emerging evidence from landmark studies like SELECT, this paper evaluates whether GLP-1 agonists represent a transformative breakthrough or an overhyped intervention with significant limitations
Understanding how GLP-1 therapy affects lipid parameters can help patients and clinicians make informed decisions about cardiovascular risk management
Combined with a healthy diet and exercise program, these treatments create a well-rounded approach to achieving lasting results
How It Works: Semaglutide imitates the action of GLP-1 hormone inciting natural insulin secretion, appetite reduction, and gastric emptying
Initially developed for Type 2 Diabetes (T2D), GLP-1 drugs are now widely used in obesity/weight loss management, with emerging applications in cardiovascular and neurodegenerative diseases